サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1439428

薬剤溶出性ステント - 世界市場の考察、競合情勢、市場予測（2030年）

Drug Eluting Stents - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
薬剤溶出性ステント - 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の薬剤溶出性ステントの市場規模は、2023年に25億7,000万米ドル、2030年までに40億8,000万米ドルに達し、2024年～2030年の予測期間にCAGRで8.09％の成長が見込まれます。

薬剤溶出性ステントの市場力学

薬剤溶出性ステント市場の注目すべき促進要因の1つは、心血管疾患の発症にも寄与する生活習慣病の有病率の上昇です。糖尿病と高血圧は、心血管疾患の発症に関連するもっとも一般的な2つの兆候です。国際糖尿病連合が引用した数字によると、2022年に20～79歳の成人5億3,700万人近くが糖尿病を患っています。同様に、世界保健機関（WHO）（2023）が提供したもう1つのデータセットでは、平均で、コレステロールの上昇により260万人が死亡すると推定されています。コレステロール値と血糖値が高いと、心筋に栄養を供給する血管系に大きな影響を与えるため、心血管系疾患の発症の可能性が高くなります。薬剤溶出性ステントは、閉塞した血管を開くだけでなく、再狭窄を避けるためにステント留置部位に薬剤を供給するのに使用されます。したがって、生活習慣病の急増による心血管疾患の有病率の増加が、このようなステントの需要を促進し、ひいては予測期間（2024年～2030年）の世界の薬剤溶出性ステント市場の成長をもたらすことが見込まれます。

薬剤溶出性ステント市場の成長をもたらすもう1つの主な要因は、老年人口の増加です。世界保健機関（WHO）が「Decade of Healthy Ageing (2020-2030) Report」で提供したデータによると、60歳以上の高齢者数は34％増加し、2019年の10億人から2030年までに14億人に増加します。同レポートはさらに、2050年までに世界の老年人口は21億人に倍増すると述べています。加齢は血管の肥厚に関係し、血管の弾力性にさらに影響を与えます。これが高齢者における動脈硬化の主な要因となっており、治療には薬剤溶出性ステントが使用されています。したがって、老年人口の増加は、血管系に対する老化の影響により薬剤溶出性ステントの需要をさらに促進し、ひいては近い将来、薬剤溶出性ステント市場の成長を後押しすると予測されます。

しかし、頻繁な製品リコールやデバイスに関連する合併症が、薬剤溶出性ステント市場の成長抑制要因になる可能性があります。

薬剤溶出性ステント市場は、COVID-19の伝染の連鎖を断ち切るために必要な措置としてロックダウンが実施されたため、短期的な市場成長の抑制が報告されました。ロックダウンの実施はサプライチェーンに大きな影響を与え、生産の混乱がデバイスの生産に影響を及ぼしました。多くの国では、COVID-19危機の間、ワークフローを合理化するために、緊急医療の必要性に基づいて医療処置を分離し、選択的と見なされるさまざまな医療処置が中断されました。そのため、製品需要は通常の水準より減少しました。しかし、医療部門を含む産業全体の活動が再開されたことで、情勢は2024年～2030年の予測期間の薬剤溶出性ステント市場にとって好転しています。

薬剤溶出性ステント市場のセグメント分析

薬剤溶出性ステント市場のコーティングセグメントでは、ポリマーコーティングカテゴリが予測期間（2024年～2030年）に薬剤溶出性ステント市場で大幅な収益成長を記録することが見込まれています。これは、ポリマーでコーティングされた薬剤溶出性ステントに関連する利点によるものと考えられます。これらのステントにコーティングされたポリマーは抗増殖薬を放出し、ステント留置後の内膜増殖を抑制して再狭窄を予防します。さらに、薬剤溶出性ステント上の生体吸収性または生分解性のポリマーは、非生分解性のものより有益です。生分解性ポリマーコーティングは薬剤が完全に放出された後、不活性金属スキャフォールド（足場材）を残して自ら分解することから、動脈治癒を改善する可能性があります。生分解性ポリマーコーティングはまた、第一世代の薬剤溶出性ステントと比較して晩期血栓症のリスクが低いです。したがって、薬剤溶出性ステントの生分解性ポリマーコーティングに関連する利点を考慮すると、この製品カテゴリはかなりの収益を生み出し、予測期間に世界の薬剤溶出性ステント市場全体の成長を押し上げると見込まれます。

当レポートでは、世界の薬剤溶出性ステント市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 薬剤溶出性ステント市場レポートのイントロダクション

第2章 薬剤溶出性ステント市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価
  • 財務ベンチマーク

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 薬剤溶出性ステント市場の主な要因の分析

  • 薬剤溶出性ステント市場の促進要因
    • 心血管疾患の有病率の増加
    • 老年人口の増加
    • 生活習慣病の有病率の増加
    • 新製品の開発への注目の高まり
  • 薬剤溶出性ステント市場の抑制要因と課題
    • 頻繁な製品リコール
    • デバイスに関連する合併症
  • 薬剤溶出性ステント市場の機会
    • 製品の安全性の向上
    • 新興国をターゲットにした製品の発売

第5章 薬剤溶出性ステント市場のポーターのファイブフォース分析

第6章 薬剤溶出性ステント市場に対するCOVID-19の影響分析

第7章 薬剤溶出性ステント市場のレイアウト

  • タイプ別
    • 冠動脈ステント留置術
    • 末梢ステント留置術
  • スキャフォールド（足場材）別
    • プラチナクロム
    • コバルトクロム
    • ニチノール
    • その他
  • コーティング別
    • ポリマーベースコーティング
    • ポリマーフリーコーティング
  • 薬剤タイプ別
    • エベロリムス
    • パクリタキセル
  • エンドユーザー別
    • 病院
    • 外来手術センター
    • 専門クリニック
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 薬剤溶出性ステント市場：世界の企業シェア分析 - 主要3～5社

第9章 薬剤溶出性ステント市場の企業と製品のプロファイル

  • Abbott
  • Medtronic
  • Boston Scientific Corporation
  • B. Braun Melsungen AG
  • BIOTRONIK
  • Cook
  • Terumo Corporation
  • Lepu Medical Technology (Beijing) Co., Ltd
  • Microport Scientific Corporation
  • Balton Sp.z.o.o
  • ENDOCOR GmbH
  • Eurocor Tech GmbH
  • Alvimedica
  • Biosensors International Group
  • Meril Life Sciences Pvt. Ltd
  • Translumina
  • Sino Medical Sciences Technology Inc
  • iVascular S.L.U
  • Sahajanand Laser Technology Limited (SLTL Group)
  • Cardionovum GmbH

第10章 KOLの見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis on Drug-Eluting Stents Market
  • Table 3: Drug-Eluting Stents Market in Global (2021-2030)
  • Table 4: Drug-Eluting Stents Market in Global by Type (2021-2030)
  • Table 5: Drug-Eluting Stents Market in Global by Scaffold (2021-2030)
  • Table 6: Drug-Eluting Stents Market in Global by Coating (2021-2030)
  • Table 7: Drug-Eluting Stents Market in Global by Drug Type (2021-2030)
  • Table 8: Drug-Eluting Stents Market in Global by End User (2021-2030)
  • Table 9: Drug-Eluting Stents Market in Global by Geography (2021-2030)
  • Table 10: Drug-Eluting Stents Market in North America (2021-2030)
  • Table 11: Drug-Eluting Stents Market in North America by Type (2021-2030)
  • Table 12: Drug-Eluting Stents Market in North America by Scaffold (2021-2030)
  • Table 13: Drug-Eluting Stents Market in Global by Coating (2021-2030)
  • Table 14: Drug-Eluting Stents Market in North America by Drug Type (2021-2030)
  • Table 15: Drug-Eluting Stents Market in North America by End User (2021-2030)
  • Table 16: Drug-Eluting Stents Market in North America by Country (2021-2030)
  • Table 17: Drug-Eluting Stents Market in the US (2021-2030)
  • Table 18: Drug-Eluting Stents Market in Canada (2021-2030)
  • Table 19: Drug-Eluting Stents Market in Mexico (2021-2030)
  • Table 20: Drug-Eluting Stents Market in Europe (2021-2030)
  • Table 21: Drug-Eluting Stents Market in Europe by Type (2021-2030)
  • Table 22: Drug-Eluting Stents Market in Europe by Scaffold (2021-2030)
  • Table 23: Drug-Eluting Stents Market in Global by Coating (2021-2030)
  • Table 24: Drug-Eluting Stents Market in Europe by Drug Type (2021-2030)
  • Table 25: Drug-Eluting Stents Market in Europe by End User (2021-2030)
  • Table 26: Drug-Eluting Stents Market in Europe by Country (2021-2030)
  • Table 27: Drug-Eluting Stents Market in France (2021-2030)
  • Table 28: Drug-Eluting Stents Market in Germany (2021-2030)
  • Table 29: Drug-Eluting Stents Market in the United Kingdom (2021-2030)
  • Table 30: Drug-Eluting Stents Market in Italy (2021-2030)
  • Table 31: Drug-Eluting Stents Market in Spain (2021-2030)
  • Table 32: Drug-Eluting Stents Market in Russia (2021-2030)
  • Table 33: Drug-Eluting Stents Market in Rest of Europe (2021-2030)
  • Table 34: Drug-Eluting Stents Market in APAC (2021-2030)
  • Table 35: Drug-Eluting Stents Market in APAC by Type (2021-2030)
  • Table 36: Drug-Eluting Stents Market in APAC by Scaffold (2021-2030)
  • Table 37: Drug-Eluting Stents Market in Global by Coating (2021-2030)
  • Table 38: Drug-Eluting Stents Market in APAC by Drug Type (2021-2030)
  • Table 39: Drug-Eluting Stents Market in APAC by End User (2021-2030)
  • Table 40: Drug-Eluting Stents Market in APAC by Country (2021-2030)
  • Table 41: Drug-Eluting Stents Market in China (2021-2030)
  • Table 42: Drug-Eluting Stents Market in Japan (2021-2030)
  • Table 43: Drug-Eluting Stents Market in India (2021-2030)
  • Table 44: Drug-Eluting Stents Market in Australia (2021-2030)
  • Table 45: Drug-Eluting Stents Market in South Korea (2021-2030)
  • Table 46: Drug-Eluting Stents Market in Rest of APAC (2021-2030)
  • Table 47: Drug-Eluting Stents Market in Rest of World (2021-2030)
  • Table 48: Drug-Eluting Stents Market in RoW by Type (2021-2030)
  • Table 49: Drug-Eluting Stents Market in RoW by Scaffold (2021-2030)
  • Table 50: Drug-Eluting Stents Market in Global by Coating (2021-2030)
  • Table 51: Drug-Eluting Stents Market in RoW by Drug Type (2021-2030)
  • Table 52: Drug-Eluting Stents Market in RoW by End User (2021-2030)
  • Table 53: Drug-Eluting Stents Market in RoW by Region (2021-2030)
  • Table 54: Drug-Eluting Stents Market in Middle East (2021-2030)
  • Table 55: Drug-Eluting Stents Market in Africa (2021-2030)
  • Table 56: Drug-Eluting Stents Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis on Drug-Eluting Stents Market
  • Figure 3: Drug-Eluting Stents Market in Global (2021-2030)
  • Figure 4: Drug-Eluting Stents Market in Global by Type (2021-2030)
  • Figure 5: Drug-Eluting Stents Market in Global by Scaffold (2021-2030)
  • Figure 6: Drug-Eluting Stents Market in Global by Coating (2021-2030)
  • Figure 7: Drug-Eluting Stents Market in Global by Drug Type (2021-2030)
  • Figure 8: Drug-Eluting Stents Market in Global by End User (2021-2030)
  • Figure 9: Drug-Eluting Stents Market in Global by Geography (2021-2030)
  • Figure 10: Drug-Eluting Stents Market in North America (2021-2030)
  • Figure 11: Drug-Eluting Stents Market in North America by Type (2021-2030)
  • Figure 12: Drug-Eluting Stents Market in North America by Scaffold (2021-2030)
  • Figure 13: Drug-Eluting Stents Market in Global by Coating (2021-2030)
  • Figure 14: Drug-Eluting Stents Market in North America by Drug Type (2021-2030)
  • Figure 15: Drug-Eluting Stents Market in North America by End User (2021-2030)
  • Figure 16: Drug-Eluting Stents Market in North America by Country (2021-2030)
  • Figure 17: Drug-Eluting Stents Market in the US (2021-2030)
  • Figure 18: Drug-Eluting Stents Market in Canada (2021-2030)
  • Figure 19: Drug-Eluting Stents Market in Mexico (2021-2030)
  • Figure 20: Drug-Eluting Stents Market in Europe (2021-2030)
  • Figure 21: Drug-Eluting Stents Market in Europe by Type (2021-2030)
  • Figure 22: Drug-Eluting Stents Market in Europe by Scaffold (2021-2030)
  • Figure 23: Drug-Eluting Stents Market in Global by Coating (2021-2030)
  • Figure 24: Drug-Eluting Stents Market in Europe by Drug Type (2021-2030)
  • Figure 25: Drug-Eluting Stents Market in Europe by End User (2021-2030)
  • Figure 26: Drug-Eluting Stents Market in Europe by Country (2021-2030)
  • Figure 27: Drug-Eluting Stents Market in France (2021-2030)
  • Figure 28: Drug-Eluting Stents Market in Germany (2021-2030)
  • Figure 29: Drug-Eluting Stents Market in the United Kingdom (2021-2030)
  • Figure 30: Drug-Eluting Stents Market in Italy (2021-2030)
  • Figure 31: Drug-Eluting Stents Market in Spain (2021-2030)
  • Figure 32: Drug-Eluting Stents Market in Russia (2021-2030)
  • Figure 33: Drug-Eluting Stents Market in Rest of Europe (2021-2030)
  • Figure 34: Drug-Eluting Stents Market in APAC (2021-2030)
  • Figure 35: Drug-Eluting Stents Market in APAC by Type (2021-2030)
  • Figure 36: Drug-Eluting Stents Market in APAC by Scaffold (2021-2030)
  • Figure 37: Drug-Eluting Stents Market in Global by Coating (2021-2030)
  • Figure 38: Drug-Eluting Stents Market in APAC by Drug Type (2021-2030)
  • Figure 39: Drug-Eluting Stents Market in APAC by End User (2021-2030)
  • Figure 40: Drug-Eluting Stents Market in APAC by Country (2021-2030)
  • Figure 41: Drug-Eluting Stents Market in China (2021-2030)
  • Figure 42: Drug-Eluting Stents Market in Japan (2021-2030)
  • Figure 43: Drug-Eluting Stents Market in India (2021-2030)
  • Figure 44: Drug-Eluting Stents Market in Australia (2021-2030)
  • Figure 45: Drug-Eluting Stents Market in South Korea (2021-2030)
  • Figure 46: Drug-Eluting Stents Market in Rest of APAC (2021-2030)
  • Figure 47: Drug-Eluting Stents Market in Rest of World (2021-2030)
  • Figure 48: Drug-Eluting Stents Market in RoW by Type (2021-2030)
  • Figure 49: Drug-Eluting Stents Market in RoW by Scaffold (2021-2030)
  • Figure 50: Drug-Eluting Stents Market in Global by Coating (2021-2030)
  • Figure 51: Drug-Eluting Stents Market in RoW by Drug Type (2021-2030)
  • Figure 52: Drug-Eluting Stents Market in RoW by End User (2021-2030)
  • Figure 53: Drug-Eluting Stents Market in RoW by Region (2021-2030)
  • Figure 54: Drug-Eluting Stents Market in Middle East (2021-2030)
  • Figure 55: Drug-Eluting Stents Market in Africa (2021-2030)
  • Figure 56: Drug-Eluting Stents Market in South America (2021-2030)
  • Figure 57: Market Drivers
  • Figure 58: Market Barriers
  • Figure 59: Marker Opportunities
  • Figure 60: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0231

Drug-Eluting Stents Market By Type (Coronary Stenting And Peripheral Stenting), By Scaffold (Platinum-Chromium, Cobalt-Chromium, Nitinol, And Others), By Coating (Polymer-Based Coating [Biodegradable And Non-Biodegradable] And Polymer-Free Coating), By Drug Type (Everomilus, Paclitaxel, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Specialty Clinics), by geography is estimated to register growth at a remarkable CAGR forecast during 2024-2030 owing to increase in aging population and growing prevalence of cardiovascular diseases

Global drug-eluting stents market was valued at USD 2.57 billion in 2023, growing at a CAGR of 8.09% during the forecast period from 2024 to 2030 to reach USD 4.08 billion by 2030. The Drug Eluting Stents market is slated to witness prosperity owing to factors such as growing prevalence of cardiovascular diseases which can further be attributed to the increase in geriatric population wherein aging is considered to have a deleterious effect on blood vessels, growing prevalence of lifestyle disorders such as hypertension, diabetes, and obesity that are linked to affect the health of blood vessels in long term and drastically increase the probability of atherosclerosis, and the growing focus on developing newer generation of drug eluting stents in order to minimize post-procedural complications are further expected to result in the appreciable revenue growth in the drug eluting stents market during the forecast period (2024-2030).

Drug-Eluting Stents Market Dynamics:

One of the noteworthy drivers of the drug-eluting stents market is the rising prevalence of lifestyle disorders that further contribute in the development of cardiovascular diseases. Diabetes and hypertension are two of the most common indications that are linked to the pathogenesis of cardiovascular diseases. As per the figures quoted by the International Diabetes Federation, in 2022, close to 537 million adults in the 20-79 year age group were living with diabetes. Similarly, in another dataset provided by the World Health Organization (2023), on an average, raised cholesterol is estimated to result in 2.6 million deaths. High levels of cholesterol and blood sugar are linked with increased chances of the development of cardiovascular diseases as they heavily impact the vasculature supplying the myocardium. Drug-eluting stents are employed in opening up the blocked blood vessels as well as also deliver drugs at the site of stent placement in order to avoid restenosis. Therefore, the increasing prevalence of cardiovascular diseases due to surge in the number of lifestyle disorders are anticipated to drive the demand for such stents eventually leading the global drug-eluting stents market growth during the forecast period (2024-2030).

Another key factor responsible for the growth of the drug-eluting stents market is the rising geriatric population. As per the data provide by the World Health Organization in their Decade of Healthy Ageing(2020-2030) Report, the number of people aged 60 years and older will be 34% higher, increasing from one billion in 2019 to 1.4 billion in 2030. The report further stated that by 2050, the global population of the elderly will get doubled to 2.1 billion. Aging has been related to thickening of blood vessels which further impacts the elasticity of blood vessels. This acts as a major factor for the development of arteriosclerosis in the elderly population, wherein the preferred mode of treatment is the employment of drug-eluting stents. Thus, the increase in the aging population is expected to further drive the demand for drug-eluting stents owing to the effects of aging on the vasculature, ultimately bolstering the growth of the drug eluting stents market in the near future.

However, frequent product recalls and device-related complications may act as restraining factors to the drug eluting stents market growth.

The drug eluting stents market reported a short period of restraint in market growth due to the implementation of lockdown as necessary measures to break the chain of the COVID-19 infection transmission. The imposing of lockdown massively affected the supply chains and production disruptions affected the device production. Many countries segregated medical procedures based on the need for urgent medical care in order to streamline the workflow during the COVID-19 crisis and saw various medical procedures considered elective being suspended. This led to the decrease in product demand from regular levels. However, with the resumption of activities across industries including the healthcare sector, it has been uplifting for the drug eluting stents market during the forecast period from 2024-2030.

Drug-Eluting Stents Market Segment Analysis:

Drug-Eluting Stents Market by Type (Coronary Stenting and Peripheral Stenting), by Scaffold (Platinum-Chromium, Cobalt-Chromium, Nitinol, and Others), by Coating (Polymer-based Coating [Biodegradable and Non-biodegradable] and Polymer-free Coating), by Drug Type (Everomilus, Paclitaxel, and Others), by End User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the coating segment of the drug-eluting stents market, the polymer-coated category is projected to register a significant growth in revenue in the drug eluting stents market during the forecast period (2024-2030). This can be ascribed to the advantages associated with the drug eluting stents coated with polymer. The polymer coating on these stents release antiproliferative drugs which prevents restenosis by inhibiting intimal proliferation after stent implantation. Additionally, bioresorbable or biodegradable polymers on drug eluting stents are advantageous over the non-biodegradable ones. The biodegradable polymer coating degrades on its own after the complete release of the drug leaving behind an inert metal scaffold in place, which may improve arterial healing. Biodegradable polymer coatings are also associated with lower risk of late thrombosis compared to first generation drug eluting stents. Therefore, considering the advantages associated with biodegradable polymer coating on drug eluting stents, this product category is expected to generate considerable revenue thereby pushing the overall growth of the global drug eluting stents market during the forecast period.

North America is expected to dominate the overall Drug-Eluting Stents Market:

Among all the regions, North America is expected to lead in revenue generation in the global drug-eluting stents market. This can be ascribed to the large presence of patient pool of cardiovascular diseases which can further be attributed to the increased reliance on junk food, sedentary lifestyle among other factors, extensive coverage both by private and public health insurance providers for the stent placement procedures, as well as increasing aging population of the elderly, among other factors in the region.

One of the key factors supporting the growth of the North America drug eluting stents market is the growing prevalence of cardiovascular diseases such as the peripheral artery disease. As per the number quoted by the Centers for Disease Control and Prevention (2023), near about 6.5 million people in the age group of 40 years and older suffer from PAD in the United States. Furthermore, it has been established that PAD can further heighten the risk for developing cerebrovascular disease and coronary artery disease. The drug-coated stents such as paclitaxel-eluting stents help in mechanically opening the blocked vessels and improve blood flow in the lower limbs which further help in improving the prognosis for patients. Therefore, the rising prevalence of peripheral artery disease in the country and the extensive use of drug-eluting stents are expected to bolster the growth of the drug eluting stents market in the United States during the forecast period.

Moreover, the data provided by the Government of Canada (2023) stated that on an average, Canadians employed in full-time employment spend 68.9% of their day remaining sedentary. This type of lifestyle has been evidenced to drastically increase the risk for many of the chronic diseases including hypertension, cholesterol which may further give rise to other cardiovascular diseases such as atherosclerosis. In events like this, drug-eluting stents are then employed in the opening up the blocked vessels as part of the treatment regimen. Thus, the decrease in physical activity and increase in sedentary behavior in the Canadian population may also contribute in the growing prevalence of risk factors such as obesity and hypertension in the population, ultimately leading to the development of various cardiovascular disorders. This may act as another stimulating factor for the drug-eluting stents market in the coming years to target the potential patient population in the country.

The increasing patient population in the region further motivate manufacturers in gaining product approvals from the local regulatory bodies. For instance, in April 2022, the Canadian medical device regulatory authority body, Health Canada granted product approval to Biotronik's Orsiro drug-eluting stent for the treatment of coronary artery disease. Local product approvals help manufacturers establish credibility in individual countries and further improving product reach on a country level.

Therefore, all the factors are collectively expected to influence the demand for such stents eventually driving the growth of the North America drug eluting stents market during the forecast period.

Drug-Eluting Stents Market Key Players:

Some of the key market players operating in the drug eluting stents market includes Abbott, Medtronic, Boston Scientific Corporation, B. Braun Melsungen AG, BIOTRONIK, Cook, Terumo Corporation, Lepu Medical Technology(Beijing)Co.,Ltd, MicroPort Scientific Corporation., Balton Sp. z o.o., ENDOCOR GmbH, Eurocor Tech GmbH., Alvimedica, Biosensors International Group, Meril Life Sciences Pvt. Ltd, Translumina, Sino Medical Sciences Technology Inc, iVascular S.L.U Sahajanand Laser Technology Limited (SLTL Group)., Cardionovum GmbH., and others.

Recent Developmental Activities in Drug-Eluting Stents Market:

In September 2022, Biotronik received the regulatory approval from the US Food and Drug Administration for their Orsiro Mission bioabsorbable polymer drug-eluting stent system (BP-DES). The device is said to feature the ultrathin strut design touted as the thinnest available design available in the United States.

In June 2022, Abbott received the product approval from the US FDA for their XIENCE family of stents for one-month (for 28 days) DAPT labeling for high bleeding risk (HBR) patients in the U.S. The product has already received the CE mark approval.

In May 2022, Alvimedica received the CE mark approval for their NiTides self-expanding, drug-eluting stent aimed for treating lesions associated with peripheral artery disease in the superficial femoral arteries.

Key Takeaways from the Drug-Eluting Stents Market Report Study

Market size analysis for current drug eluting stents market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the drug eluting stents market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, joint ventures happened for last 3 years

Key companies dominating the global drug eluting stents market.

Various opportunities available for the other competitor in the drug eluting stents market space.

What are the top performing segments in 2023? How these segments will perform in 2030.

Which is the top-performing regions and countries in the current drug eluting stents market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for drug eluting stents market growth in the coming future?

Target Audience who can be benefited from this Drug-Eluting Stents Market Report Study

Drug Eluting Stents products providers

Research organizations and consulting companies

Drug Eluting Stents-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in drug eluting stents

Various end users who want to know more about the drug eluting stents market and latest technological developments in the drug eluting stents market.

Frequently Asked Questions for Drug-Eluting Stents Market:

1. What is a drug eluting stent?

A drug-eluting stent is a small mesh structure which is inserted into the artery to keep it open and also releases a medication which helps in preventing the formation of blood clots inside the stent.

2. What is the market for Global Drug Eluting Stents?

Global drug-eluting stents market was valued at USD 2.57 billion in 2023, growing at a CAGR of 8.09% during the forecast period from 2024 to 2030 to reach USD 4.08 billion by 2030.

3. What are the drivers for Global Drug Eluting Stents Market?

The Drug Eluting Stents market is slated to witness prosperity owing to factors such as growing prevalence of cardiovascular diseases which can further be attributed to the increase in geriatric population wherein aging is considered to have a deleterious effect on blood vessels, growing prevalence of lifestyle disorders such as hypertension, diabetes, and obesity that are linked to affect the health of blood vessels in long term and drastically increase the probability of atherosclerosis, and the growing focus on developing newer generation of drug eluting stents in order to minimize post-procedural complications are further expected to result in the appreciable revenue growth in the drug eluting stents market during the forecast period (2024-2030).

4. Who are the key players operating in Global Drug Eluting Stents Market?

Some of the key market players operating in the drug eluting stents market includes Abbott, Medtronic, Boston Scientific Corporation, B. Braun Melsungen AG, BIOTRONIK, Cook, Terumo Corporation, Lepu Medical Technology(Beijing)Co.,Ltd, MicroPort Scientific Corporation., Balton Sp. z o.o., ENDOCOR GmbH, Eurocor Tech GmbH., Alvimedica, Biosensors International Group, Meril Life Sciences Pvt. Ltd, Translumina, Sino Medical Sciences Technology Inc, iVascular S.L.U Sahajanand Laser Technology Limited (SLTL Group)., Cardionovum GmbH., and others.

5. Which region has the highest share in Drug Eluting Stents market?

North America is expected to dominate the overall Surgical Robotic Systems market during the forecast period, 2024 to 2030. This can be ascribed to the large presence of patient pool of cardiovascular diseases which can further be attributed to the increased reliance on junk food, sedentary lifestyle among other factors, extensive coverage both by private and public health insurance providers for the stent placement procedures, as well as increasing aging population of the elderly, among other factors in the region.

Table of Contents

1.Drug Eluting Stents Market Report Introduction

2.Drug Eluting Stents Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment
  • 2.4. Financial Benchmarking

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Drug Eluting Stents Market Key Factors Analysis

  • 4.1. Drug Eluting Stents Market Drivers
    • 4.1.1. Increasing Prevalence of Cardiovascular Diseases
    • 4.1.2. Rising Geriatric Population
    • 4.1.3. Growing Prevalence of Lifestyle Disorders
    • 4.1.4. Increasing Focus on Developing New Products
  • 4.2. Drug Eluting Stents Market Restraints and Challenges
    • 4.2.1. Frequent Product Recalls
    • 4.2.2. Device-Related Complications
  • 4.3. Drug Eluting Stents Market Opportunities
    • 4.3.1. Improving Product Safety
    • 4.3.2. Targeting Emerging Economies for Product Launches

5. Drug Eluting Stents Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Drug Eluting Stents Market

7. Drug Eluting Stents Market Layout

  • 7.1. By Type
    • 7.1.1. Coronary Stenting
    • 7.1.2. Peripheral Stenting
  • 7.2. By Scaffold
    • 7.2.1. Platinum-Chromium
    • 7.2.2. Cobalt-Chromium
    • 7.2.3. Nitinol
    • 7.2.4. Others
  • 7.3. By Coating
    • 7.3.1. Polymer-based Coating
      • 7.3.1.1. Biodegradable
      • 7.3.1.2. Non-Biodegradable
    • 7.3.2. Polymer-Free Coating
  • 7.4. By Drug Type
    • 7.4.1. Everolimus
    • 7.4.2. Paclitaxel
    • 7.4.3. Others
  • 7.5. By End User
    • 7.5.1. Hospitals
    • 7.5.2. Ambulatory Surgical Centers
    • 7.5.3. Specialty Clinics
  • 7.6. By Geography
    • 7.6.1. North America
      • 7.6.1.1. North America Drug-Eluting Stents Market, by Type
      • 7.6.1.2. North America Drug-Eluting Stents Market, by Scaffold
      • 7.6.1.3. North America Drug-Eluting Stents Market, by Coating
      • 7.6.1.4. North America Drug-Eluting Stents Market, by Drug Type
      • 7.6.1.5. North America Drug-Eluting Stents Market, by End User
      • 7.6.1.6. North America Drug-Eluting Stents Market, by Country
      • 7.6.1.6.1. United States
      • 7.6.1.6.2. Canada
      • 7.6.1.6.3. Mexico
    • 7.6.2. Europe
      • 7.6.2.1. Europe Drug-Eluting Stents Market, by Type
      • 7.6.2.2. Europe Drug-Eluting Stents Market, by Scaffold
      • 7.6.2.3. Europe Drug-Eluting Stents Market, by Coating
      • 7.6.2.4. Europe Drug-Eluting Stents Market, by Drug Type
      • 7.6.2.5. Europe Drug-Eluting Stents Market, by End User
      • 7.6.2.6. Europe Drug-Eluting Stents Market, by Country
      • 7.6.2.6.1. France
      • 7.6.2.6.2. Germany
      • 7.6.2.6.3. United Kingdom
      • 7.6.2.6.4. Italy
      • 7.6.2.6.5. Spain
      • 7.6.2.6.6. Russia
      • 7.6.2.6.7. Rest of Europe
    • 7.6.3. Asia-Pacific
      • 7.6.3.1. Asia-Pacific Drug-Eluting Stents Market, by Type
      • 7.6.3.2. Asia-Pacific Drug-Eluting Stents Market, by Scaffold
      • 7.6.3.3. Asia-Pacific Drug-Eluting Stents Market, by Coating
      • 7.6.3.4. Asia-Pacific Drug-Eluting Stents Market, by Drug Type
      • 7.6.3.5. Asia-Pacific Drug-Eluting Stents Market, by End User
      • 7.6.3.6. Asia-Pacific Drug-Eluting Stents Market, by Country
      • 7.6.3.6.1. China
      • 7.6.3.6.2. Japan
      • 7.6.3.6.3. India
      • 7.6.3.6.4. Australia
      • 7.6.3.6.5. South Korea
      • 7.6.3.6.6. Rest of Asia Pacific
    • 7.6.4. Rest of the World (RoW)
      • 7.6.4.1. RoW Drug-Eluting Stents Market, by Type
      • 7.6.4.2. RoW Drug-Eluting Stents Market, by Scaffold
      • 7.6.4.3. RoW Drug-Eluting Stents Market, by Coating
      • 7.6.4.4. RoW Drug-Eluting Stents Market, by Drug Type
      • 7.6.4.5. RoW Drug-Eluting Stents Market, by End User
      • 7.6.4.6. RoW Drug-Eluting Stents Market, by Region
      • 7.6.4.6.1. Middle East
      • 7.6.4.6.2. Africa
      • 7.6.4.6.3. South America

8. Drug-Eluting Stents Market Global Company Share Analysis - Key 3-5 Companies

9. Drug-Eluting Stents Market Company and Product Profiles

  • 9.1. Abbott
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4. Product Listing
    • 9.1.5. Entropy
  • 9.2. Medtronic
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4. Product Listing
    • 9.2.5. Entropy
  • 9.3. Boston Scientific Corporation
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4. Product Listing
    • 9.3.5. Entropy
  • 9.4. B. Braun Melsungen AG
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4. Product Listing
    • 9.4.5. Entropy
  • 9.5. BIOTRONIK
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4. Product Listing
    • 9.5.5. Entropy
  • 9.6. Cook
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4. Product Listing
    • 9.6.5. Entropy
  • 9.7. Terumo Corporation
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4. Product Listing
    • 9.7.5. Entropy
  • 9.8. Lepu Medical Technology(Beijing)Co.,Ltd
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4. Product Listing
    • 9.8.5. Entropy
  • 9.9. Microport Scientific Corporation
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4. Product Listing
    • 9.9.5. Entropy
  • 9.10. Balton Sp.z.o.o
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4. Product Listing
    • 9.10.5. Entropy
  • 9.11. ENDOCOR GmbH
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4. Product Listing
    • 9.11.5. Entropy
  • 9.12. Eurocor Tech GmbH
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4. Product Listing
    • 9.12.5. Entropy
  • 9.13. Alvimedica
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4. Product Listing
    • 9.13.5. Entropy
  • 9.14. Biosensors International Group
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4. Product Listing
    • 9.14.5. Entropy
  • 9.15. Meril Life Sciences Pvt. Ltd
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4. Product Listing
    • 9.15.5. Entropy
  • 9.16. Translumina
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4. Product Listing
    • 9.16.5. Entropy
  • 9.17. Sino Medical Sciences Technology Inc
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4. Product Listing
    • 9.17.5. Entropy
  • 9.18. iVascular S.L.U
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4. Product Listing
    • 9.18.5. Entropy
  • 9.19. Sahajanand Laser Technology Limited (SLTL Group)
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4. Product Listing
    • 9.19.5. Entropy
  • 9.20. Cardionovum GmbH
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4. Product Listing
    • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us